1. Home
  2. CIVB vs PRTC Comparison

CIVB vs PRTC Comparison

Compare CIVB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civista Bancshares Inc.

CIVB

Civista Bancshares Inc.

HOLD

Current Price

$23.84

Market Cap

500.4M

Sector

Finance

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.46

Market Cap

464.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIVB
PRTC
Founded
1884
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
500.4M
464.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CIVB
PRTC
Price
$23.84
$17.46
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$26.00
N/A
AVG Volume (30 Days)
97.6K
3.9K
Earning Date
01-29-2026
08-28-2025
Dividend Yield
3.02%
N/A
EPS Growth
31.34
N/A
EPS
2.64
0.20
Revenue
$169,173,000.00
$6,391,000.00
Revenue This Year
$15.24
N/A
Revenue Next Year
$6.52
N/A
P/E Ratio
$9.03
$8.37
Revenue Growth
13.47
1265.60
52 Week Low
$17.47
$13.30
52 Week High
$25.59
$20.00

Technical Indicators

Market Signals
Indicator
CIVB
PRTC
Relative Strength Index (RSI) 52.07 45.00
Support Level $23.35 $18.31
Resistance Level $25.40 $18.98
Average True Range (ATR) 0.82 0.54
MACD -0.06 -0.18
Stochastic Oscillator 43.50 5.75

Price Performance

Historical Comparison
CIVB
PRTC

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: